Custom service

Anti-Drug Antibody Assay Development & Validation

Develop and validate ada assays fit for their intended regulatory use

Turnaround: 8–14 weeksTypical scale: µg – g sample scaleChemistry options: tiered assay strategy (screen/confirm/titer/NAb); matrix tolerance characterization; validation report per regulatory guidance

The service is built around tiered assay strategy (screen/confirm/titer/NAb). Depending on the molecule we may move to matrix tolerance characterization or validation report per regulatory guidance to improve stability, loading or yield, and every batch is released with validated ADA assay with validation report.

Because Anti-Drug Antibody Assay Development & Validation projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

IND-enabling immunogenicity packages

Assay rescue for failed validations

Assays for products outside peptide/protein space

Samples requiring containment or licensing we do not hold (BSL-3, radioactive)

Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.

Service Highlights

  • Tiered assay strategy (screen/confirm/titer/NAb) as the default route, with matrix tolerance characterization held as a proven fallback
  • Validation report per regulatory guidance worked into the design where the application requires it
  • Results are reported with detection limits and method validation status, so you know exactly what the number means
  • Analytical confirmation of every intermediate before the final release
  • Orthogonal methods are used by default — one measurement is an observation, two are data
  • Validated ADA assay with validation report delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sample intake & plan

    Samples are logged with chain of custody and the test matrix for Anti-Drug Antibody Assay Development & Validation is confirmed.

  2. Method selection

    Analytical methods — tiered assay strategy (screen/confirm/titer/NAb), matrix tolerance characterization — are chosen and their validation status documented.

  3. Measurement

    Testing is executed with system-suitability checks and orthogonal confirmation where required.

  4. Data review

    Chromatograms and spectra are reviewed by a second analyst before any result is issued.

  5. Reporting

    Validated ADA assay with validation report is issued with detection limits and interpretation notes.

  6. Follow-up support

    We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.

Specifications & timeline

Turnaround
8–14 weeks
Typical scale
µg – g sample scale
Chemistry options
tiered assay strategy (screen/confirm/titer/NAb); matrix tolerance characterization; validation report per regulatory guidance
Deliverable
Validated ADA assay with validation report
QC package
Method report, raw data, validated result with detection limits
Shipping
Blue ice or ambient by material; chain-of-custody on receipt

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.